论文部分内容阅读
自1979年1月～1985年12月,我们应用MTX—CF 治疗恶性滋养细胞肿瘤34例(恶葡28例,绒癌6例),其中Ⅰ期25例(占73.5%)、Ⅱ_A期4例、Ⅱ_B 期1例、Ⅲ_A 期3例、Ⅳ期1例。单一用MTX-CF 治疗辅以切宫(9例)的21例(Ⅰ期16例,占80%)全部获得近期治愈。应用其他化疗药物2个疗程以上产生耐药而改用MTX-CF 治疗的13例中获近期治愈的有11例(84.6%)。因此,我们认为MTX-CF 治疗非转移性滋养细胞肿瘤有很高的疗效,即使是转移性滋养细胞肿瘤,应用其他化疗药物产生耐药后改用MTX-CF 治疗仍有较好的疗效。
From January 1979 to December 1985, we used MTX-CF to treat 34 cases of malignant trophoblastic tumors (28 cases of eosinophils and 6 cases of choriocarcinoma), of which 25 cases (73.5%) were in stage I and 4 cases in stage II_A. 1 case of II_B stage, 3 cases of III_A stage, and 1 case of IV stage. Twenty-one cases (16 cases in phase I, accounting for 80%) of MTX-CF alone supplemented with uterine excision (9 cases) were all cured shortly. Among the 13 patients who developed resistance using more than two courses of chemotherapeutic drugs and were treated with MTX-CF, 11 (84.6%) were cured recently. Therefore, we believe that MTX-CF is highly effective in the treatment of non-metastatic trophoblastic tumors. Even for metastatic trophoblastic tumors, the use of other chemotherapeutic agents for resistance to MTX-CF after treatment has a good effect.